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1. Introduction 
The paucity of literature in pediatric neurotransmitter diseases indicates a gap in our 
understanding of neurochemistry and the clinical phenomenology. However, the dramatic 
clinical responses to dopaminergic therapy in dopa-responsive dystonias opened avenues 
for rationalizing this therapeutic approach in other pediatric neurotransmitter disorders. 
This chapter aims to link up dopaminergic therapy, dystonia and other pediatric 
neurotransmitter diseases. It was in 1971 that Segawa (Segawa et al., 1971, 1976) reported 
patients with child-onset periodic dystonia, whose dystonia had diurnal variation, with 
towards evening being worse with walking. The symptom was recovered in the morning. 
Unlike other dystonic disorders, levodopa was effective to alleviate involuntary movements 
in those patients. (Tarsy et al., 2006) This disease was later named as Dopa responsive 
dystonia (DRD), DYT-5, or Segawa disease. (Nygaard et al., 1988) 
In 1994, Ichinose et al. detected that the cause of Segawa disease was heterozygous defect of 
guanosine triphosphate cyclohydrolase I (GTPCH) located at 14q22-q22.2. (Ichinose et al., 
1994)  GTPCH is a rate-limiting enzyme of tetrahydrobiopterin (BH4) synthesis from 
guanosine triphosphate (GTP). (Shintaku, 2002)  BH4 is co-factor of aromatic amino acids 
hydroxylase. Tyrosine hydroxylase (TH) is one of aromatic amino acids hydroxylase and it 
is a rate-limiting enzyme of dopamine synthesis. In Segawa disease, decrease of BH4 is 
considered to suppress the activity of TH and dopamine production. Dopamine begins to be 
used up after waking up and the individual becomes active. In effect, the total amount of 
dopamine in terminals of dopaminergic neurons decrease in the evening, when dystonic 
symptoms occur. At night, during sleep as one rests, dopamine is recharged such that upon 
waking up, no dystonia is noted (Furukawa et al., 1999, 2002; Segawa et al., 2003). 
It was reported that other diseases showed symptoms of dystonia and other movement 
disorders that were responsive for L-dopa. There were tyrosine hydroxylase deficiency and 
sepiapterin reductase (SR) deficiency. Defect of several other enzymes that were related BH4 
metabolism, that is, 6-pyruvoyl tetrahydropterin synthase deficiency, dihydropteridine 
reductase deficiency, and autosomal recessive GTPCH deficiency also demonstrate dopa-
responsive involuntary movements. However, those disorders have been considered as 
diseases related phenylketonuria, for those diseases showed hyperphenylalaninemia and it is 
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important to reduce phenylalanine concentration in central nervous system (CNS) in patients 
with those diseases. Some patients with familial parkinsonism also indicated dopa-responsive 
movement disorder that was resemble for Segawa disease. (Tassin et al., 2000) However, those 
diseases were considered as a parkinsonism and were not considered as PNDs. 
2. Pediatric neurotransmitter diseases 
In addition to Segawa disease, several disorders related to dopamine/serotonin metabolism 
have been reported. Disorders of gamma amino butyric acid (GABA) metabolism were also 
rare metabolic diseases. They were all rare inherited metabolic diseases. Those disorders 
were called as pediatric neurotransmitter diseases (PND) (Swoboda et al., 2002; Pearl et al., 
2007), for they showed involuntary movements due to defect or excess of neurotransmitters 
from childhood. In this report, the author described summary of clinical manifestations and 
current treatments of those diseases.  
2.1 Disease of BH4 metabolism 
BH4 is constructed from GTP by several enzymes. Defect of these enzymes decrease the 
amount of BH4. As BH4 work as co-factor of each aromatic amino acids hydroxylase, 
suppression of BH4 production affect the synthesis of neurotransmitters. As kinetics of each 
aromatic amino acids hydroxylase was different, degree of suppression of BH4 synthesis is 
important to decide the manifestation of each patient. Complete defect of BH4 causes 
hyperphenylalaninemia, for all of each aromatic amino acids hydroxylase. Those diseases 
are usually classified as disorders related phenylketonuria and are not considered as PNDs. 
Two disorders, Segawa disease and Sepiapterin reductase (SR) deficiency, are classified as 
PNDs, for these diseases indicate normal serum phenylalanine concentration. 
In this section, the author described about those two diseases. 
However no essential difference was existed between the two diseases and other BH4 
deficiency. Plasma phenylalanine level of Segawa disease was significantly higher than 
those of controls. (See Fig.1)  However the values of plasma phenylalanine were within the 
normal range (less than 2 mg/dl or 121 µmol/l). (Fujioka et al., 2009)  Activity of 
phenylalanine hydroxylase was slightly suppressed in Segawa disease patients. In this 
chapter, diseases of BH4 deficiency with hyperphenylalaninemia are also described simply.  
2.1.1 Segawa disease 
Segawa disease was first reported PNDs and caused by partial defect of GTPCH. (Segawa et 
al., 1971; Ichinose et al., 1994)  This disorder is autosomal dominant inheritance with 
incomplete penetrance. (Furukawa et al., 1998)  Most of patients showed dystonic symptoms 
before 7 year-old. Adult-onset Segawa disease was also reported. (Turjanski et al., 1993)  
Number of female patients was reported to 2 to 6 times higher than those of male patients. 
(Furukawa et al., 1998)  The most popular symptom of Segawa disease is postural dystonia. 
(Segawa et al., 2003)  In these patients, often dystonia in one side of legs was observed. The 
dystonic symptoms were often spread to both sides of upper and lower limbs around 15 year-
old. Muscle rigidity progressed around 20 year-old. After that, most of their symptoms were 
fixed. In a part of these patients, postural tremor was also observed. In other patients, action 
dystonia was observed. Those patients often showed involuntary movements after 8 year-old. 
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Their symptoms were often upper-limb dystonia, cervical dystonia, or oculogyric crisis. After 
the age of young adult, they also showed spasmodic torticollis, or writer’s cramp. Some 
patients with action type Segawa disease showed paroxysmal kinesigenic dyskinesia or 
restless leg syndrome-like symptoms. Adult-onset type Segawa disease patients showed 
spasmodic torticollis, or writer’s cramp, parkinsonism-like symptoms. 
 
Fig. 1. Comparison of plasma phenylalanine (Phe) and Tyrosine (Tyr) concentration. 
(Modified from Fujioka et al., 2009) 
Analysis of variance indicated that plasma phenylalanine concentration of Segawa disease 
was higher than those of other group (asterisk: p<0.05). However, the value was within the 
normal range (less than 121µmol/l). No significant difference was observed in plasma 
tyrosine concentration. 
Usually patients of Segawa disease did not show psychomotor delay or convulsion. Their 
locomotion was also normal. However some Action type patients showed depression. Several 
patients who occurred symptoms during infantile periods often showed autistic tendency, 
depression, obsessive-compulsive disorders, or headache that suggested shortage of serotonin. 
In those patients, decrease of muscle tonus or abnormality of locomotion was also observed.  
To diagnose Segawa disease is difficult, for its symptom is broad. (Chaila et al., 2006)  Gene 
analysis of GTPCH enzyme is one of good method to diagnose Segawa disease, however, 
mutation of GCH1 gene, which is coding GTPCH, has been reported various. Some reports 
described that a part of patients with dopa-responsive dystonia and clinically diagnosed as 
Segawa disease did not have any mutation in GCH1 gene. (Zirn et al., 2008)  Biochemical 
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diagnose of Segawa disease has also been reported. One method is oral phenylalanine 
loading test. (Hyland et al., 1997; Bandmann et al., 2003; Opladen et al., 2010)  As activity of 
GTPCH of Segawa disease patients is lower than that of control, amount of neopterin, a 
metabolite of biopterin synthesis pathway (Fig. 2) in cerebrospinal fluids (CSF) is expected 
to decrease. (Fujita et al., 1990; Furukawa et al., 1993; Bandmann et al., 1996)  Amount of 
BH4 in CNS of patient with Segawa disease also decreased. (Furukawa et al., 1999) 
 
Fig. 2. Scheme of Tetrahydrobiopterin Synthesis and metabolism. 
Tetrahydrobiopterin is synthesized from GTP by GTP cyclohydrolase I (GTPCH), 
Sepiapterin reductase (SR), and other enzymes. BH4 is a co-factor of each aromatic amino 
acid hydroxylase. Tyrosine hydroxylase (TH) is one of aromatic amino acid hydroxylase, 
which convert Tyrosine into L-dopa. 
As described in original reports, levodopa was effective to many of Segawa disease patients. 
The maximum dose of levodopa is 20 mg/kg/day. (Segawa et al., 2003; Furusho et al., 1993)  
Carbidopa is an inhibitor of dopa decarboxylase. To use drugs of the levodopa/carbidopa 
combination, amount of L-dopa delivering to neurons was increasing, for it prevent to 
convert L-dopa to dopamine outside the blood-brain barrier. (Nagata et al., 2007; Bernard et 
al., 2010)  In recent report, low dose levodopa and selegiline was helpful. (Yosunkaya et al., 
2010)  However, in some patients of action type Segawa disease, levodopa was not effective, 
for it was considered that the dysfunction of D1 receptor of dopaminergic neurons in 
hypothalamus. (Segawa et al., 2003)  In these patients, D1 agonists would be effective. In 
patients showed shortage of serotonin, 5-hydroxy tryptophan that was the precursor of 
serotonin would be effective. BH4 is also effective in these patients, for it is known as a co-
factor of both tyrosine hydroxylase and tryptophan hydroxylase, which were the rate-
limiting enzymes of synthesis of dopamine and serotonin. 
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As many of Segawa disease are female and their symptoms occur from childhood, a part of 
them should be pregnant with symptoms and L-dopa replacement therapy. Treatment of 
Segawa disease during pregnancy has been reported. (Watanabe et al., 2009)  A report from 
Japan, levodopa monotherapy is relatively safe. Six pregnancies with levodopa 
monotherapy (Levodopa: 250 mg/day) were safe and three pregnancies were fatal loss, two 
of them were treated with levodopa/carbidopa (100 mg levodopa + 10 mg carbidopa) and 
the rest one of them was treated without any medication. 
2.1.2 Sepiapterin reductase (SR) deficiency 
Sepiapterin reductase deficiency has been reported by a patient with progressive 
psychomotor delay with increase of biopterin and dihydrobyopterin and decrease of 5-
hydroxy acetic acid (5-HIAA) and homovanilic acid. (Bonafé et al., 2001)  Many of patients 
were reported around Mediterranean. (Neville et al., 2005)  Sepiapterin reductase is one of 
enzymes to covert sepiapterin into BH4. (See Fig.2) 
Patients from Malta showed early motor delay and a significant degree of cognitive 
impairment. Diurnal variation of the motor impairments and oculogyric crisis occurred from 
an early stage. Hypotonia was apparent in early stage and later, dystonia was observed. Some 
of them showed Parkinsonian tremor or chorea. Some of them showed bulbar involvements. 
L-dopa dramatically improved motor problems including dystonia, chorea, and oculogyric 
crisis in those patients. After the treatment, many of them were able to walk. There was no 
obvious response to cognitive function with learning. In SR deficiency, dysfunction of 
serotonin was also suspected. It is possible that 5-hydroxy tryptophan is also effective with 
SR deficiency, for 5-HTP is the precursor of serotonin. Initial dose of L-dopa was 1.5 to 4 
mg/kg/day (12.5 to 50 mg/day). (Neville et al., 2005)  In these patients, 100 mg L-dopa and 
10 mg Carbidopa tablets were used. One case report described incomplete response to 
treatment during short-term follow-up. (Kusmierska et al., 2009) 
 
Diseases Segawa Disease SR deficiency
Cause of Gene GTPCH I (Heterozygous) Sepiapterin Reductase (SR) 
Inheritance Autosomal Dominant Autosomal Recessive 
Involuntary Movement Postural Dystonia, Tremor Motor Delay, hypotension 
Action Dystonia Oculogyric crisis, writer's cramp 
Convulsion Very Rare Rare
Intellectual Normal Delay
Hyperphenylalaninemia - -
CSF Neopterin Level Decrease Normal
CSF Biopterin Level Decrease Increase
Dopa Responsibility + +
Diagnosis Gene analysis, decrease Gene analysis
of CSF neopterin
Treatment 
L-dopa (or L-dopa with 
carbidopa)*
L-dopa with carbidopa 
*carbidopa is not recommended with pregnant women. 
Table 1. Disorders of BH4 metabolism 
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2.1.3 other tetrahydrobiopterin defects with hyperphenylalaninemia 
Tetrahydrobiopterin is a co-factor of aromatic amino acids hydroxylase. There are three 
aromatic amino acids hydroxylase, which are tyrosine hydroxylase, tryptophan 
hydroxylase, and phenylalanine hydroxylase. (Fig. 2)  Decrease of tetrahydrobiopterin in 
liver down-regulates the activity of phenylalanine hydroxylase and blood phenylalanine 
concentration increase. These include autosomal-recessive GTPCH deficiency (Opladen et 
al., 2011), pterin-carbinolamin dehydratase deficiency, dihydropteridine reductase 
deficiency, and 6-pyruvoyl tetrahydropterin synthase deficiency. (Shintaku, 2002)  All are 
autosomal recessive inheritance disorders. 
Defect of phenylalanine hydroxylase causes phenylketonuria (PKU) and the most common 
treatment of PKU is restriction of protein. Large neutral amino acid is another treatment, 
which decrease brain phenylalanine level.  
In contrast, oral administration of tetrahydrobiopterin rapidly normalizes 
hyperphenylalaninemia s with disorders of tetrahydrobiopterin deficiency. Unlike normal 
PKU, protein restriction is not effective to decrease serum phenylalanine concentration. 
Treatment of BH4 deficiency is administration of BH4 (10 mg/kg/day). (Shintaku, 2002)  
Recently, tetrahydrobiopterin responsive PKU was reported and administration of 
tetrahydrobiopterin is a new treatment of PKU. 
Oral supplementation of BH4 improves the activity of liver phenylalanine hydroxylase and 
normalizes blood phenylalanine concentration. (Shintaku et al., 2004) 
However administration of BH4 does not improve movement disorder due to shortage of 
dopamine and/or serotonin in CNS, for BH4 do not go through blood-brain barrier. To 
improve their movement disorders due to insufficient dopamine and/or serotonin, 
administration of precursor of dopamine and/ or serotonin is necessary to go through 
blood-brain barrier. Clinically, levodopa and 5-HTP are often used to patients with BH4 
deficiency. Carbidopa are also used in addition to levodopa. 
2.2 Disease of monoamine metabolism 
Tyrosine hydroxylase deficiency and Aromatic amino acids decarboxylase deficiency are 
classified as disorders of monoamine synthesis. In these diseases, symptoms are induced by 
decrease of amounts of monoamines. Monoamines include dopamine, serotonin, 
noradrenaline, adrenaline, histamine and other catecholamine. Diseases classified as 
monoamine breakdown includes monoamine oxidase deficiency and dopamine β-
hydroxylase deficiency. 
2.2.1 Tyrosine hydroxylase deficiency 
Tyrosine Hydroxylase (See Fig. 2 and 3) converts tyrosine into L-dopa, and is a rate-limiting 
enzyme of dopamine synthesis. (Castaigne et al., 1971; Rondot et al., 1983, 1992)  Most of 
patients with tyrosine hydroxylase deficiency showed progressive encephalopathy. (DE 
Lonlay et al., 2000; Hoffmann et al., 2003)  Some other patients showed typical dopa-
effective dystonia. Unlike to Segawa disease, neopterin and biopterin concentration in CSF 
are normal. (Lüdecke et al., 1996) 
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The former severe type shows axial hypotonia, hypokinesia, and facial mimicry within a few 
months after birth. After that, increase of deep tendon reflexes, pyramidal movement 
disorder, oculogyric crisis, ptosis, miosis, and prolonged diurnal periods of lethargy with 
increased sweating alternated with irritability are also observed. The progress of those 
symptoms would be sometimes lethal. No effective treatment has been reported. Recently 
trial of deep brain stimulation was reported to improve severe involuntary movements with 
a TH deficiency patient. (Tormenti et al., 2011) 
The latter mild type patients show involuntary movements responsible for levodopa 
however did not show any psychomotor delay or convulsion. Their dystonic symptoms and 
rigidity occur during infantile period. Many of these patients show lower limb dystonia and 
then the dystonic symptoms spread to other lesions. Some patients also show tremor. They 
are treatable by levodopa as Segawa Disease. (Willemsen et al., 2010)  
2.2.2 Aromatic amino acid decarboxylase (AADC) deficiency 
Aromatic amino acids decarboxylases convert L-dopa into dopamine and 5-HTP into 
serotonin. (See Fig.3) Patients of AADC deficiency showed intermittent oculogyric crisis and 
dystonia of four limbs before 6 month-old. (Korenke et al., 1997; Swoboda et al., 1999, 2003)  
Irritability, ocular convergence spasm, facial dystonia, myoclonus, and dysfunction of 
voluntary movements were often observed. Hypotonia and increase of deep tendon reflex 
were observed. Many of patients were lawn down and were not able to speak. However, the 
symptoms of AADC deficiency were various, for a mild type patient showed only a mild 
hypotonia and ptosis. The patient could walk and talk. Some of the patients would be 
misdiagnosed as cerebral palsy. FDG-PET findings indicated decrease of sugar metabolism 
at striatum. (Sato et al., 2006; Ide et al., 2010)  Dysfunction of basal ganglia should be a cause 
of abnormal movements. 
 
Fig. 3. Structure and Function of Aromatic l-amino acid decarboxylase (AADC). 
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Due to shortage of catecholamine, sweating, breath holding, diarrhea, and ptosis were 
observed in most patients with AADC deficiency. In some patients, convulsion due to 
hypoglycemia was reported. (Korenke et al., 1997; Swoboda et al., 1999, 2003)  Sleep 
disorder was also observed in a part of patients, for amount of melatonin is decreased in 
patients with AADC deficiency. Melatonin is synthesized from serotonin and amount of 
serotonin often decrease in patients with AADC deficiency. Some patients have epilepsy 
or abnormal electroencephalogram. (Pearl et al., 2007; Bräutigam et al., 2002; Ito  
et al., 2008) 
Tyrosine and Tryptophan are converted into L-dopa and 5-HTP by their aromatic acids 
hydroxylase. The produced L-dopa and 5-HTP are converted into dopamine and serotonin 
by aromatic l-amino acids decarboxylase (AADC). Increase of L-dopa and decrease of 
dopamine is observed in CNS when AADC do not work in patients with AADC deficiency, 
for dopamine is not allowed to go through blood brain barrier 
Dopamine agonists, monoamine oxidase inhibitors, and vitamin B6 are used as a medication 
for AADC deficiency. Vitamin B6 is a co-factor of AADC. (Pons et al., 2004; Brun et al., 2010)  
However these drugs has not been improved the symptoms of AADC deficiency patients 
well. Now, gene therapy is expected as a novel therapy for those patients. As the construct 
of brain in AADC deficiency patients are normal, their symptoms is expected to be 
improved when AADC enzyme work well in their brain. (Manegold et al., 2009; Allen et al., 
2009; Jarraya et al., 2009) 
 
Diseases TH deficiency AADC deficiency 
Cause of Gene Tyrosine Hydroxylase 
Aromatic L-amino acid 
Decarboxylase 
Inheritance Autosomal Recessive Autosomal Recessive 
Involuntary 
Movement 
DRD, Oculogyric crisis, 
Progressive encephalitis Postural Dystonia of extremities 
Convulsion Rare Not common 
Intellectual DRD type: normal, 
Delay 
encephalitis type: delay 
Diagnosis Gene analysis, decrease Gene analysis, increase of 
of Homovanilic acid (HVA) L-dopa and 5-HTP 
Dopa Responsibility + - 
Treatment L-dopa (DRD), Dopamine agonist, MAO inhibitor, 
  None (encephalitis) Vit. B6, Gene therapy 
Table 2. Disorders of Dopamine metabolism 
2.2.3 Monoamine oxidase deficiency 
Monoamine oxidase (MAO) has two isotypes, MAO A and MAO B. Both genes are on the X 
chromosome. Mutation of MAO A gene was reported in a large family. (Brunner et al., 1993)  
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All affected males showed mild mental retardation and aggressive behaviour. No MAO B 
deficiency has been reported.  
2.2.4 Dopamine β-hydroxylase deficiency 
Dopamine β-hydroxylase is a copper-dependent enzyme and it converts dopamine into 
noradrenalin. Dopamine β-hydroxylase deficiency (Robertson et al., 1986) is rare autosomal 
recessive disorder and showed orthostatic hypotension due to deficit in autonomic 
regulation. Other symptoms of this disease are impaired ejaculation, ptosis, nocturia, hyper 
flexible joint, high palate, nasal stiffness, and so on. (Robertson et al. 1991)  To treat 
orthostatic hypotension, L-threo-3, 4-dihydroxyphenylserine (DOPS) were reported. 
(Biagginoni et al., 1986; Freeman et al., 1991) 
2.3 Disorders of GABA metabolism 
Gamma amino butyric acid is important inhibitory neurotransmitters. Failure of GABA 
regulation induces various neurologic symptoms. Glutamic acid decarboxylase (GAD) 
deficiency is disorder of GABA synthesis. GABA transaminase deficiency and succinic 
semialdehyde dehydrogenase (SSADH) deficiency are disorders of GABA breakdown. 
2.3.1 Glutamic acid decarboxylase (GAD) deficiency 
Glutamic acid decarboxylase (GAD) synthesizes GABA from glutamate. GAD1 deficiency is 
autosomal recessive inheritance and it was reported that the disease was a cause of non-
progressive form of spastic cerebral palsy. (Lynex et al., 2004)  Other report described that 
animal model of GAD deficiency was related to cleft palate. (Asada et al., 1997)  Suppression 
of GAD by autoantibody was reported to relate Batten disease (Pearce et al., 2001) or 
epilepsy. (McKnight et al., 2005) 
2.3.2 GABA transaminase deficiency 
GABA transaminase (See Fig.4) converts GABA into succinate. Deficiency of GABA 
transaminase is autosomal recessive inheritance. Only three reports have been published 
about patients with GABA transaminase deficiency. They showed severe psychomotor 
retardation, hypotonia, hyperreflexia, lethargy, and refractory seizures. (Jaeken et al., 1984; 
Medina-Kauwe et al., 1999; Tsuji et al., 2010)  The patients showed growth acceleration due 
to elevation of serum growth hormone concentration. Increase of GABA in blood and CSF is 
important to diagnose GABA transaminase deficiency. The recent study described that 
increase of intracranial GABA was detected by proton magnetic resonance spectroscopy 
(1H-MRS). (Tsuji et al., 2010)  This report also described that the prenatal exposure of GABA 
was responsible for the clinical manifestation of this disease, for GABA worked as an 
excitatory molecule early in life. 
2.3.4 Succinic semialdehyde dehydrogenase (SSADH) deficiency 
Succinic semialdehyde dehydrogenase (SSADH) converts succinic semialdehyde into 
succinate. (See Fig.4)  In SSADH deficiency patients, dysfunction of SSADH causes increase 
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of 4-hydroxybutylic acids. (Gibson et al., 1983; Rating et al., 1984)  However, it is not 
confirmed that 4-hydroxybutylic acids is the cause of symptoms, for the substance negate 
the symptoms of SSADH deficiency when it was administrated for patients or model 
animals. SSADH deficiency is one of disorders of gamma amino butyric acid (GABA) 
metabolism. 
Symptoms of SSADH deficiency are mild to moderate developmental delay, severe 
hypotonia, sleep disorder, attention deficit, hyperactivity, anxiety, decrease of deep tendon 
reflex, non-progressive cerebellar ataxia, and convulsions. Most of SSADH patients are non-
progressive. However, 10% of SSADH patients are progressive. Cranial T2 weighted MRI 
indicated high signal in both side of globus pallidus. (Pearl et al. 2011, Yamakawa  
et al. 2011) 
No effective treatment is known. In a part of patients, vigabatrin (gamma vinyl GABA) is 
reported to improve symptoms of ataxia. Vigabatrin is an inhibitor of GABA transaminase. 
(Gibson et al., 1989, 1995; Gropman et al., 2003) 
 
Fig. 4. Metabolism of GABA and SSADH deficiency 
GABA is converted into succinic semialdehyde by GABA transaminase. Succinic 
semialdehyde is catalysed to 4-hydroxybutyric acid and succinic acid. In patients with 
succinic semialdehyde dehydrogenase (SSADH) deficiency, Succinic acid decrease and 4-
hydroxybutyric acid increase. 
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Diseases GAD deficiency 
GABA transaminase 
deficiency 
SSADH deficiency 
Inheritance Autosomal Recessive Autosomal Recessive Autosomal Recessive 
Involuntary  Spastic cerebral palsy 
Psychomotor delay, 
hypotonia 
Motor delay, hypotonia, 
Movement Cleft palate? 
hyperreflexia, lethargy, 
seizure 
convulsion, sleep 
disorder, 
Convulsion relation to epilepsy? common common 
Intellectual Delay Delay Delay 
Diagnosis Gene Analysis 
Increase of blood and 
CSF GABA 
Gene analysis, increase 
of 
  
proton MRS 
urine gamma-hydroxy 
butyrate 
Treatment None None Vigabatrin 
Table 3. Disorders of GABA metabolism 
3. Conclusion 
Pediatric neurotransmitter diseases were induced by congenital defects of 
neurotransmitters. Diseases related to dopamine/serotonin system affected basal ganglia 
and patients showed dystonia and other involuntary movements. L-dopa was effective to 
those disorders, for those symptoms were induced by shortage of dopamine in central 
nervous system. L-dopa is a precursor of dopamine and is able to go through blood-brain 
barrier. So oral administrated L-dopa is converted into dopamine in brain. Administration 
of dopamine is no effect because it does not go through blood-brain barrier. In patients with 
AADC deficiency, L-dopa is not effective. In those patients, dopamine is not synthesized 
from L-dopa in CNS, for AADC is inactive. (See Fig. 3) 
Some of patients of PNDs show decrease of serotonin. Psychiatric symptoms including 
depression, sleep disorder, obsessive-compulsive disorders, or headache is often observed 
when serotonin deficiency occurs. In those patients, 5-HTP is useful to supply serotonin, for 
5-HTP is a precursor of serotonin and is able to go through blood-brain barrier. 
Tetrahydrobiopterin (BH4) is co-factors of dopamine and serotonin synthesis. (Fig. 2)  
Administration of BH4 is useful to reduce hyperphenylalaninemia in liver. The 
administration of BH4 could increase the production of innate L-dopa or 5-HTP at outside of 
CNS, for BH4 do not go thorough blood brain barrier. However, BH4 is insufficient to 
improve intracranial abnormality of dopamine and serotonin.  Administration of L-dopa 
and 5-HTP to the patients with biopterin deficiency is necessary to prevent appearance of 
symptoms due to shortage of neurotransmitters. 
Carbidopa is an inhibitor of aromatic amino acids decarboxylase. To administrate carbidopa 
with levodopa increase the amount of levodopa arriving at CNS to reduce degradation of L-
dopa before blood-brain barrier. By using carbidopa and levodopa, total dose of levodopa 
for patients with PNDs could decrease. Other type of PNDs is due to dysfunction of GABA 
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metabolic system. In this manuscript, the author described SSADH deficiency. Previous 
reports described that an inhibitor of GABA transaminase improved their psychomotor 
dysfunction al least partially. 
AADC deficiency is one of disorders that L-dopa is ineffective. Gene therapy has been 
expected to improve symptoms of these patients. To replace abnormal enzyme to normal 
enzyme is enable to convert L-dopa into dopamine in CNS and supplement of dopamine is 
expected to suppress involuntary movements. 
Botulinum toxin therapy (A Pickett and R L Rosales. 2011) and deep brain stimulation (DBS) 
(K L Collins et al. 2010) have each been shown to be effective mangaement approaches in 
dystonia. Botulinum toxin is often used in focal dystonia and DBS is usually treated by 
general dystonia. Both two therapies have not been applied for PNDs because symptoms 
due to PNDs are often improved by administration of L-dopa. However, in severe patients 
or patients who are not response to L-dopa, those two therapies will be considered as an 
alternative therapies. 
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